World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
23227
World Ranking
15217
National Ranking
7676

Thomas A. Aloia publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Thomas A. Aloia sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 478 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Thomas A. Aloia D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas A. Aloia sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Thomas A. Aloia is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans medicine with a focus on oncology, surgery, and hepatology. Additional areas of study include economics and econometrics, as well as public health, environmental, and occupational health.

Their work covers a range of topics, notably:

  • Hepatocellular carcinoma treatment and prognosis
  • Pancreatic and hepatic oncology research
  • Colorectal cancer treatments and studies
  • Economic and financial impacts of cancer
  • Enhanced recovery after surgery
  • Cholangiocarcinoma and gallbladder cancer studies
  • COVID-19 and healthcare impacts

Thomas A. Aloia has published extensively in several journals. The most frequent publication venues include:

  • Gastroenterology
  • Annals of Surgical Oncology
  • HPB
  • Annals of Surgery
  • Journal of Gastrointestinal Surgery

The scientist has collaborated regularly with several co-authors, among whom the most frequent are:

  • Ching-We D. Tzeng
  • Yun Shin Chun
  • Timothy E. Newhook
  • Jean-Nicolas Vauthey
  • Hop S. Tran Cao

Several notable papers authored or co-authored by Thomas A. Aloia include:

  • "Guidelines for Perioperative Care for Pancreatoduodenectomy: Enhanced Recovery After Surgery (ERAS) Recommendations 2019," 2020, World Journal of Surgery
  • "Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons," 2020, Annals of Surgery
  • "Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience," 2021, Annals of Surgical Oncology
  • "A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status," 2020, Journal of the National Comprehensive Cancer Network
  • "Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status," 2021, British Journal of Surgery

Best Publications

  • Liver Histology and Surgical Outcomes After Preoperative Chemotherapy With Fluorouracil Plus Oxaliplatin in Colorectal Cancer Liver Metastases

    Thomas A Aloia;Mylène Sebagh;Marylène Plasse;Vincent Karam

  • Hepatic Resection for Noncolorectal Nonendocrine Liver Metastases: Analysis of 1452 Patients and Development of a Prognostic Model

    René Adam;Laurence Chiche;Thomas A Aloia;Dominique Elias

  • Solitary Colorectal Liver Metastasis: Resection Determines Outcome

    Thomas A. Aloia;Jean Nicolas Vauthey;Evelyne M. Loyer;Dario Ribero

  • Is liver resection justified for patients with hepatic metastases from breast cancer

    René Adam;Thomas A Aloia;Jinane Krissat;Marie Pierre Bralet

  • Gallbladder cancer: expert consensus statement.

    Thomas A. Aloia;Nicolas Járufe;Milind Javle;Shishir K. Maithel

  • Hilar Cholangiocarcinoma: expert consensus statement

    John C. Mansour;Thomas A. Aloia;Christopher H. Crane;Julie K. Heimbach

  • RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

    Jean Nicolas Vauthey;Giuseppe Zimmitti;Scott E. Kopetz;Junichi Shindoh

  • Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?

    René Adam;Dennis A Wicherts;Robbert J de Haas;Thomas Aloia

  • Selection for hepatic resection of colorectal liver metastases: expert consensus statement

    Reid B. Adams;Thomas A. Aloia;Evelyne Loyer;Timothy M. Pawlik

  • Kinetic Growth Rate after Portal Vein Embolization Predicts Posthepatectomy Outcomes: Toward Zero Liver-Related Mortality in Patients with Colorectal Liver Metastases and Small Future Liver Remnant

    Junichi Shindoh;Mark J. Truty;Thomas A. Aloia;Steven A. Curley

  • A Proposed Staging System for Intrahepatic Cholangiocarcinoma

    Hari Nathan;Thomas A. Aloia;Jean Nicolas Vauthey;Eddie K. Abdalla

  • Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach

    Junichi Shindoh;Jean Nicolas Vauthey;Giuzeppe Zimmitti;Steven A. Curley

  • Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis

    Randa Tao;Sunil Krishnan;Priya R. Bhosale;Milind M. Javle

  • Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival.

    Yoshihiro Mise;Thomas A. Aloia;Kristoffer W. Brudvik;Lilian Schwarz

  • Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

    Keri E Lunsford;Milind Javle;Kirk Heyne;Rachna T Shroff

  • Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.

    René Adam;Thomas A Aloia;Francis Lévi;Dennis A. Wicherts

  • Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement

    René Adam;Robbert J. de Haas;Dennis A. Wicherts;Thomas A. Aloia

  • Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study.

    Junichi Shindoh;Xabier de Aretxabala;Thomas A Aloia;Juan C arlos Roa

  • Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases

    Junichi Shindoh;Evelyne M. Loyer;Scott Kopetz;Piyaporn Boonsirikamchai

  • Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy.

    Andreas Andreou;Thomas A. Aloia;Antoine Brouquet;Paxton V. Dickson

Frequent Co-Authors

Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Cathy Eng
Cathy Eng Vanderbilt University
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Xuemei Wang
Xuemei Wang The University of Texas MD Anderson Cancer Center
Timothy M. Pawlik
Timothy M. Pawlik The Ohio State University Wexner Medical Center
James L. Abbruzzese
James L. Abbruzzese Duke University
Jennifer A. Chan
Jennifer A. Chan University of Calgary
Andrew X. Zhu
Andrew X. Zhu Harvard University
Richard D. Schulick
Richard D. Schulick University of Colorado Anschutz Medical Campus

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in the healthcare field but not sure if medical school is the right fit? There are a range of rewarding online degree programs and alternative pathways to a medical career. For those who prefer an administrative role, a healthcare administration online degree can prepare you for leadership positions in hospitals, clinics, or insurance organizations—all from the comfort of your home.

If you’re focused on quick entry into the workforce, medical billing and coding offers fast-track options. Explore top medical billing and coding online schools, many of which provide flexible schedules and financial aid opportunities.

Nursing is another in-demand field with streamlined online options. Curious about prerequisites? Find out, for example, do I need to take the teas test for LPN and learn more about programs that remove traditional testing barriers.

For registered nurses aiming to advance, bridge programs like the ASN to NP path help expedite the route to nurse practitioner roles—boosting career growth without pressing pause on your professional life.

Best Scientists Citing Thomas A. Aloia

Trending Scientists

Recently Published Articles